emvododstat   Click here for help

GtoPdb Ligand ID: 11421

Synonyms: PTC-299 | PTC299
Compound class: Synthetic organic
Comment: Emvododstat (PTC299) is an orally bioavailable inhibitor of dihydroorotate dehydrogenase (DHODH) that was developed by PTC Therapeutics [1] for anti-cancer potential. It inhibits de novo pyrimidine nucleotide (UMP) biosynthesis and exhibits broad activity against leukemia in vitro and in vivo.

SARS-CoV-2: Emvododstat inhibits replication of SARS-CoV-2 in vitro (EC50 2.0-31.6 nM) and other RNA viruses [2]. It blocks production of inflammatory cytokines in infected cell cultures.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 54.56
Molecular weight 466.09
XLogP 6.27
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES COc1ccc(cc1)[C@@H]1N(CCc2c1[nH]c1c2cc(cc1)Cl)C(=O)Oc1ccc(cc1)Cl
Isomeric SMILES COc1ccc(cc1)[C@@H]1N(CCc2c1[nH]c1c2cc(cc1)Cl)C(=O)Oc1ccc(cc1)Cl
InChI InChI=1S/C25H20Cl2N2O3/c1-31-18-7-2-15(3-8-18)24-23-20(21-14-17(27)6-11-22(21)28-23)12-13-29(24)25(30)32-19-9-4-16(26)5-10-19/h2-11,14,24,28H,12-13H2,1H3/t24-/m0/s1
No information available.
Summary of Clinical Use Click here for help
Emvododstat (PTC299) was originally evaluated in cancer, but has been redeployed for anti-viral activity in COVID-19 patients.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04439071 A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19) Phase 2/Phase 3 Interventional PTC Therapeutics
NCT00508586 PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer Phase 1 Interventional PTC Therapeutics
NCT03761069 Study of PTC299 in Relapsed/Refractory Acute Leukemias Phase 1 Interventional PTC Therapeutics